PD149163 decreases operant responding for METH in mice.

<p>(A) Systemic injection (s.c.) of both doses of PD149163 resulted in a significant decrease in nose pokes (FR3) made during 2-hour operant METH self-administration sessions. * <i>P</i> < 0.05 versus saline, Dunnett’s multiple comparison test. (B) Both doses of PD149163 also produced a significant decrease in number of METH infusions. * <i>P</i> < 0.05 versus saline, Dunnett’s multiple comparison test.</p

Rotarod performance is non-significantly impaired by pretreatment with PD149163.

<p>Mice injected with PD149163 (0, 0.05, 0.1 mg/kg) showed no significant main effect of drug (<i>P</i> = 0.08) or time (<i>P</i> = 0.38) on their ability to stay on a fixed speed rotating rod for up to 2 hours after drug injection.</p

PD149163 impairs voluntary locomotion in an open field beginning 10 minutes until at least 120 minutes following injection.

<p>(A) Horizontal distance traveled during the 30-minute session in 5-minute bins beginning immediately following PD149163 injection. (B) PD149163 at both doses tested almost completely eliminated voluntary locomotion 90–120 minutes after injection.</p